Clinical Trials Browser

INDUSTRY × Glioma × pembrolizumab × Clear all

NCT05366062 2022-05-13

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

Phase 2 Not yet recruiting

28 enrolled

CNS

Glioma

NCT02798406 2021-07-15

CAPTIVE

Phase 2 Completed

49 enrolled

CNSSarcoma

Brain Neoplasms, Disease, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue, Nervous System Diseases, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Gliosarcoma